N. Rieth

发表

TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis

P. Nelson, E. Noessner, I. Luettichau, 2009, Cancer Immunology, Immunotherapy.

A Novel CXCL10-Based GPI-Anchored Fusion Protein as Adjuvant in NK-Based Tumor Therapy

P. Nelson, E. Noessner, C. Lapa, 2013, PloS one.

Treatment of dermal fibroblasts with GPI-anchored human TIMP-1 protein moderates processes linked to scar formation.

P. Nelson, S. Notohamiprodjo, E. Noessner, 2013, The Journal of investigative dermatology.

Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells.

A. Carle, M. Müller, N. Rieth, 2014, Immunology letters.

Peritumoral administration of GPI-anchored TIMP-1 inhibits colon carcinoma growth in Rag-2 γ chain-deficient mice

P. Nelson, R. Djafarzadeh, N. Rieth, 2009, Biological chemistry.

Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling

S. Zahler, P. Neth, K. Kehe, 2012, Proceedings of the National Academy of Sciences.

Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

S. Segerer, P. Nelson, D. Anz, 2011, The American journal of pathology.

Cell surface engineering of renal cell carcinoma with glycosylphosphatidylinositol-anchored TIMP-1 blocks TGF-β1 activation and reduces regulatory ID gene expression

P. Nelson, S. Notohamiprodjo, Peter J Nelson, 2012, Biological chemistry.

Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

S. Segerer, P. Nelson, D. Anz, 2011, The American journal of pathology.